This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drugs

Jim Cramer -- FireEye and Other Cybersecurity Firms Are a Long-Term Play

In the view of TheStreet's Jim Cramer, while some cybersecurity companies aren't making money now, they're likely to later.

05/27/15 - 05:22 PM EDT

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer answers your Twitter questions about FireEye (FEYE) and other stocks from the floor of the New York Stock Exchange.

05/27/15 - 03:55 PM EDT

Try Jim Cramer's Action Alerts PLUS
How to Use Options to Profit From Johnson & Johnson's Success

How to Use Options to Profit From Johnson & Johnson's Success

  • Tickers in this article:
  • JNJ

Johnson & Johnson shares should move higher eventually, and here's how to use options to make money from such a move.

05/27/15 - 12:02 PM EDT

AbbVie (ABBV) Stock Gains on Bullish JPMorgan Note

AbbVie (ABBV) Stock Gains on Bullish JPMorgan Note

  • Tickers in this article:
  • ABBV

AbbVie (ABBV) is gaining after having coverage resumed with an 'overweight' rating and $75 price target at JPMorgan.

05/27/15 - 11:42 AM EDT

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.

05/26/15 - 02:27 PM EDT

AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase

AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase

  • Tickers in this article:
  • ABBV

AbbVie (ABBV) shares gained today after the company announced the completion of its purchase of Pharmacyclics

05/26/15 - 12:42 PM EDT

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

05/26/15 - 12:34 PM EDT

4 Big Biotech Companies to Sell Now

4 Big Biotech Companies to Sell Now

Biotech stocks are one of the hottest investment areas these days, but not all biotech stocks are smart buys.

05/26/15 - 08:30 AM EDT

Saluting the Monster Wave in Health Care Mergers and Recognizing Signs of a True Recovery: Jim Cramer's Best Blogs

Saluting the Monster Wave in Health Care Mergers and Recognizing Signs of a True Recovery: Jim Cramer's Best Blogs

Catch up on Jim Cramer's ideas this past week on how the recovery really will begin (hint: think household formation) and his take on the health care consolidation trend.

05/22/15 - 09:04 PM EDT

5 Investments That Show John Paulson Knows How to Play M&A

5 Investments That Show John Paulson Knows How to Play M&A

John Paulson said in a 2014 interview that he expected high levels of M&A activity to continue "for the foreseeable future." He has invested accordingly, and it is paying off.

05/22/15 - 12:28 PM EDT

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

05/22/15 - 06:01 AM EDT

CVS Health Agrees to Acquire Omnicare for $98 Per Share

CVS Health Agrees to Acquire Omnicare for $98 Per Share

  • Tickers in this article:
  • CVS
  • OCR

CVS Health Corp. said Thursday it is acquiring Omnicare Inc. for $98 per share in cash, for a total enterprise value of approximately $12.7 billion.

05/21/15 - 05:03 PM EDT

BP Settles With Transocean, Halliburton; Crude Oil Tops $60

BP Settles With Transocean, Halliburton; Crude Oil Tops $60

Wall Street edged higher in midday trading Thursday, given a slight boost by energy stocks after crude oil topped $60 a barrel.

05/21/15 - 11:50 AM EDT

IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

  • Tickers in this article:
  • ISR

IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy but makes up for it by issuing a lot of promotional press releases.

05/21/15 - 11:36 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs